STADA Arzneimittel AG (ETR:SAZ) received a €66.00 ($75.86) price objective from equities researchers at Kepler Capital Markets in a report released on Tuesday, July 4th. The firm currently has a “neutral” rating on the stock.
SAZ has been the topic of several other reports. Commerzbank Ag set a €66.00 ($75.86) target price on shares of STADA Arzneimittel AG and gave the stock a “neutral” rating in a research report on Tuesday, June 20th. Warburg Research set a €60.00 ($68.97) price objective on shares of STADA Arzneimittel AG and gave the company a “neutral” rating in a research report on Wednesday, June 28th. Independent Research GmbH set a €66.00 ($75.86) target price on shares of STADA Arzneimittel AG and gave the company a “neutral” rating in a research note on Monday, June 12th. Finally, S&P Global set a €66.00 ($75.86) target price on shares of STADA Arzneimittel AG and gave the company a “neutral” rating in a research note on Monday, May 29th. Five investment analysts have rated the stock with a hold rating, STADA Arzneimittel AG presently has an average rating of “Hold” and an average target price of €64.90 ($74.60).
STADA Arzneimittel AG (ETR:SAZ) traded down 0.124% on Tuesday, reaching €65.454. 677 shares of the company traded hands. The company has a market capitalization of €4.07 billion and a P/E ratio of 38.639. STADA Arzneimittel AG has a 12 month low of €41.40 and a 12 month high of €67.60. The company has a 50-day moving average price of €63.85 and a 200-day moving average price of €58.96.
TRADEMARK VIOLATION WARNING: This piece was originally posted by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this piece on another domain, it was copied illegally and reposted in violation of United States & international copyright laws. The correct version of this piece can be read at https://sportsperspectives.com/2017/07/24/stada-arzneimittel-ag-etrsaz-pt-set-at-66-00-by-kepler-capital-markets-updated-updated.html.
About STADA Arzneimittel AG
Stada Arzneimittel AG is a Germany-based holding company active in the pharmaceutical sector and healthcare market. The Company develops and markets products with off-patent active pharmaceutical ingredients. The Company’s primary business segments are Generics and Branded Products. The Generics segment comprises low-priced and active-ingredient products.
Receive News & Ratings for STADA Arzneimittel AG Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for STADA Arzneimittel AG and related companies with MarketBeat.com’s FREE daily email newsletter.